Entry Point Capital, LLC Axsome Therapeutics, Inc. Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
A detailed history of Entry Point Capital, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Entry Point Capital, LLC holds 171 shares of AXSM stock, worth $15,935. This represents 0.02% of its overall portfolio holdings.
Number of Shares
171
Previous 437
60.87%
Holding current value
$15,935
Previous $34.9 Million
60.53%
% of portfolio
0.02%
Previous 0.03%
Shares
2 transactions
Others Institutions Holding AXSM
# of Institutions
288Shares Held
40.4MCall Options Held
365KPut Options Held
428K-
Rtw Investments, LP New York, NY4.63MShares$432 Million6.23% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$349 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.3MShares$308 Million0.01% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA2.36MShares$220 Million37.71% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.85MShares$173 Million4.89% of portfolio
About Axsome Therapeutics, Inc.
- Ticker AXSM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,878,000
- Market Cap $4B
- Description
- Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...